SCF API DEVELOPMENT PIPELINE
API: Entry Inhibitor — gp120–CD4 Interface Blocker
Profile Code: SCF-API-HIV-ENTRY-gp120-001
Program: SCF-Fibonacci HIV Therapy Program
Therapeutic Focus: HIV/AIDS
Fibonacci Position: Step 1 — Viral Entry (Primary Gate)
SCF Role Intent: Preventative / Resistance-Preventive
1. Phase Objective
Phase 2 converts the Phase 1 scouting logic into a structured candidate-space analysis by defining the extractable or engineerable bioactive classes most compatible with a gp120–CD4 interface blocker. For this API, the objective is not bulk natural-product extraction for broad antiviral screening. It is selective extraction-and-translation of scaffold classes that can be developed into:
- gp120 interface shields,
- conformational locking modulators, or
- peptide-mimetic surface blockers.
The Phase 2 standard remains unchanged from the discovery profile: blockade of productive gp120–CD4 engagement without triggering gp120 activation, without CD4 down-modulation, and without immune suppression.
2. Phase 2 Entry Criteria
Phase 1 established the target-constrained discovery gates. Entry into Phase 2 is therefore authorized only for source-informed scaffold families that meet all of the following:
Criterion | Required Standard |
Target Logic | Viral-envelope directed, not host-CD4 directed |
Mechanistic Logic | Steric masking, closed-state stabilization, or receptor-docking interference |
Safety Logic | No primary host receptor depletion, membrane lysis, or broad cytotoxicity |
Resistance Logic | Preferential engagement of structurally conserved gp120 determinants |
Translational Logic | Convertible to medicinal chemistry, peptidomimetic, or semisynthetic optimization |
3. Phase 2 Candidate Bioactive Classes
At this phase, candidate classes are defined as scaffold categories rather than validated leads. The purpose is to organize extractable or engineerable chemistry into SCF-relevant development buckets.
3.1 Class A — Polyphenolic / Aromatic Surface-Binding Scaffolds
Phase 2 Rationale
Polyphenol-rich and aromatic planar chemotypes can support extracellular surface engagement and multi-point noncovalent interactions. In the SCF framework, these are useful only if they can be refined away from nonspecific protein adhesion and toward selective viral-surface masking.
Potential Utility
- Surface occupancy at conserved docking topography
- Multi-contact interface interference
- Early extracellular action
Primary Risk
- Nonspecific binding
- Aggregation artifacts
- Poor developability if left as crude natural-product chemistry
SCF Disposition
- Accept as inspiration space
- Advance only if selectivity engineering is feasible
3.2 Class B — Glycan-Interacting or Carbohydrate-Mimetic Surface Modulators
Phase 2 Rationale
Because HIV envelope architecture is highly glycosylated, glycan-aware scaffold space is relevant if it permits localized engagement of envelope topology without broad host-glycoprotein disruption.
Potential Utility
- Envelope-surface recognition enhancement
- Conformational influence via peripheral site occupancy
- Extracellular viral selectivity hypothesis
Primary Risk
- Host glycoprotein cross-reactivity
- Undesired lectin-like broad immunologic effects
SCF Disposition
- Moderate-priority exploration
- Advance only under stringent host-selectivity filters
3.3 Class C — Triterpenoid / Terpenoid Conformational Modulators
Phase 2 Rationale
Rigid or semi-rigid hydrophobic scaffolds may support conformational restraint if properly decorated for polarity and target-directed binding. This class is more relevant to the “closed-state” strategy than to direct docking mimicry.
Potential Utility
- Conformational locking
- Stabilization of non-productive envelope state
- Possible long-acting formulation compatibility
Primary Risk
- Off-target membrane interaction
- Solubility and exposure limitations
SCF Disposition
- High-interest for closed-state programs
- Requires strong PK rescue strategy
3.4 Class D — Cyclic Peptide / Peptide-Mimetic Surface Blockers
Phase 2 Rationale
This is the most directly aligned class for steric blockade of the gp120–CD4 interface. Structured peptides, constrained peptidomimetics, or semisynthetic macrocycles can be designed to cover docking geometry while minimizing CD4 mimic-triggered activation.
Potential Utility
- High-affinity interface shielding
- Shape-directed specificity
- Strong alignment with extracellular viral targeting
Primary Risk
- Potential conformational triggering if architecture too closely mimics CD4 contact logic
- Delivery complexity
- Proteolytic stability limitations
SCF Disposition
- Priority class
- Best fit for precision interface blockade, provided non-activating geometry is preserved
3.5 Class E — Small-Molecule Interface Shields
Phase 2 Rationale
Medicinal-chemistry-amenable small molecules remain the preferred class for oral or broadly scalable adjunctive therapy, provided they can engage conserved gp120 contact space without functioning as activating mimetics.
Potential Utility
- Oral feasibility
- Combination compatibility
- Scalable optimization and manufacturability
Primary Risk
- Insufficient contact area
- False-positive biochemical interference
- Escape risk if contact footprint is too narrow
SCF Disposition
- Co-priority class with peptide-mimetics
- Favored where developability exceeds steric limitations
4. SCF Role Assignment by Candidate Class
Candidate Class | Primary SCF Role | Secondary SCF Role | Fibonacci Fit | Development Preference |
Polyphenolic surface binders | Preventative | Resistance-preventive | Step 1 | Conditional |
Glycan-aware modulators | Preventative | Topology-modulating | Step 1 | Conditional |
Triterpenoid conformational modulators | Preventative | Conformational restraint | Step 1 | High-interest |
Cyclic peptide / peptidomimetic blockers | Preventative | Precision surface blockade | Step 1 | Priority |
Small-molecule interface shields | Preventative | Resistance-preventive | Step 1 | Priority |
5. Phase 2 MoA and MeA Assignment Framework
This phase assigns candidate classes to a standardized SCF MoA/MeA architecture.
5.1 Mechanism of Action Categories
MoA Category | Definition for This API | Best-Matched Candidate Class |
Surface Shielding | Occupies gp120 docking surface needed for CD4 engagement | Small molecule, cyclic peptide |
Conformational Locking | Stabilizes non-productive envelope state and prevents opening dynamics | Triterpenoid-like rigid modulators, select small molecules |
Steric Docking Blockade | Physically obstructs productive receptor approach | Cyclic peptide, peptidomimetic |
Envelope Topology Modulation | Alters presentation of entry-relevant surface features without receptor triggering | Glycan-aware modulators, select surface binders |
5.2 Mechanism of Effect Categories
MeA Node | Effect Sequence | Required Outcome |
Authority Node | Viral attachment permission | Denied |
Trigger Node | gp120 opening and co-receptor exposure | Suppressed |
Replication Gate | Fusion and post-entry initiation | Aborted |
Reservoir Logic | Founder infection and seeding | Reduced |
Resistance Logic | Replicative population expansion | Constrained early |
6. Extraction-to-Translation Model
For this program, “extraction” includes both literal natural-product extraction and translational extraction of scaffold logic into drug-like architectures.
Phase 2 Stream | Purpose | Output Type |
Natural-product extraction stream | Capture unique chemotypes from ethnomedical source classes | Crude actives, fractions, dereplicated scaffold families |
Scaffold abstraction stream | Strip source chemistry down to pharmacophoric logic | Privileged motifs, pharmacophore maps |
Drug-likeness translation stream | Rebuild active motifs into developable lead space | Small molecules, peptidomimetics, semisynthetic analogs |
SCF compatibility stream | Align each candidate to Step 1 preventative role | Go/no-go ranking matrix |
7. Five-Axis SCF Analysis
7.1 Axis 1 — Targeted Drug Action
Candidate Class | Targeting Assessment |
Polyphenolic surface binders | Weak-to-moderate unless narrowed to selective viral-envelope interactions |
Glycan-aware modulators | Moderate if host-glycoprotein cross-reactivity is controlled |
Triterpenoid conformational modulators | Moderate-to-strong for closed-state strategy |
Cyclic peptide / peptidomimetic blockers | Strongest for geometric precision |
Small-molecule interface shields | Strong if sufficient conserved contact footprint is achieved |
Phase 2 Interpretation
Priority remains with cyclic peptide/peptidomimetic blockers and small-molecule interface shields.
7.2 Axis 2 — Pharmacokinetic Optimization
Candidate Class | PK Outlook | Key Need |
Polyphenolic surface binders | Weak native PK | Stabilization and nonspecificity reduction |
Glycan-aware modulators | Variable | Controlled extracellular exposure |
Triterpenoid conformational modulators | Moderate | Solubility engineering |
Cyclic peptide / peptidomimetic blockers | Moderate-to-weak native PK | Protease protection, depot or injectable logic |
Small-molecule interface shields | Strongest PK potential | Oral or long-acting optimization |
Phase 2 Interpretation
Small molecules lead on PK tractability; peptides lead on precision but will require formulation support.
7.3 Axis 3 — Metabolic Efficiency
Candidate Class | Metabolic Efficiency Outlook |
Polyphenolic surface binders | Often poor without derivatization |
Glycan-aware modulators | Uncertain; depends on architecture |
Triterpenoid conformational modulators | Often durable but solubility-limited |
Cyclic peptide / peptidomimetic blockers | Requires stabilization |
Small-molecule interface shields | Best optimization latitude |
Phase 2 Interpretation
Drug-like small molecules and constrained peptidomimetics are preferred over unrefined botanical actives.
7.4 Axis 4 — Resistance Prevention
Candidate Class | Resistance Barrier Assessment |
Polyphenolic surface binders | Moderate if multi-contact; weak if nonspecific |
Glycan-aware modulators | Moderate |
Triterpenoid conformational modulators | Strong if conserved-state locking is real |
Cyclic peptide / peptidomimetic blockers | Strong if broad conserved footprint is achieved |
Small-molecule interface shields | Moderate-to-strong depending on breadth of contact map |
Phase 2 Interpretation
Conserved-surface multi-contact engagement is the central advancement criterion.
7.5 Axis 5 — Safety Profile
Candidate Class | Safety Assessment |
Polyphenolic surface binders | Risk of promiscuity |
Glycan-aware modulators | Risk of host glycoprotein effects |
Triterpenoid conformational modulators | Monitor membrane effects |
Cyclic peptide / peptidomimetic blockers | Favorable if virus-restricted |
Small-molecule interface shields | Favorable if host-interface avoidance is maintained |
Phase 2 Interpretation
Virus-restricted peptide-mimetic and carefully engineered small-molecule programs remain preferred.
8. Preliminary Candidate Ranking
Tier 1 — Primary Advancement Classes
- Cyclic peptide / peptidomimetic surface blockers
- Small-molecule gp120 interface shields
Tier 2 — Secondary Advancement Classes
- Triterpenoid-like conformational locking modulators
Tier 3 — Conditional Exploration Classes
- Glycan-aware topology modulators
- Polyphenolic surface-binding scaffolds
9. Phase 2 Lead Architecture Recommendation
At the end of Phase 2, the recommended development architecture is a dual-track discovery model:
Track A — Precision Surface Blockade Program
- Constrained peptide-mimetic
- Objective: broad conserved-surface steric interference
- Best suited for potency-first and long-acting injectable exploration
Track B — Drug-Like Interface Shield Program
- Small-molecule conserved-interface blocker
- Objective: oral or scalable adjunctive entry blockade
- Best suited for PK and combination compatibility
Track C — Closed-State Modulator Backup Program
- Conformational locking small molecule or semisynthetic rigid scaffold
- Objective: suppress gp120 opening without receptor mimicry
- Best suited as resistance-preventive backup path
10. Phase 2 Go / No-Go Filters
Go
Advance a class to Phase 3 only if it satisfies all of the following conceptual standards:
Filter | Go Standard |
Non-activating behavior | No predicted gp120 opening trigger |
Viral selectivity | Envelope-focused engagement, not CD4 antagonism |
Conserved footprint | Broad enough contact logic to reduce single-site escape |
Development tractability | Can be optimized into a manufacturable lead |
Combination logic | Clean compatibility with RT and integrase inhibitor stacks |
No-Go
Terminate or demote a class if any of the following dominate:
Filter | No-Go Standard |
Activation risk | CD4-mimetic triggering of envelope opening |
Host-risk profile | CD4 modulation, membrane toxicity, immune suppression |
Narrow mutable dependency | Overreliance on variable loop contacts |
Poor translational value | Crude antiviral activity without scaffold path |
PK infeasibility | No plausible route to useful extracellular exposure |
11. Phase 2 Decision Statement
Phase 2 Outcome: Completed as a conceptual extraction-and-analysis stage.
Authorized Advancement Set:
- Cyclic peptide / peptidomimetic surface blockers
- Small-molecule gp120 interface shields
- Backup exploration of conformational locking modulators
Deferred / Conditional Set:
- Glycan-aware modulators
- Polyphenolic surface binders
Strategic Conclusion:
The SCF profile is best advanced as a dual-track Step 1 preventative program centered on non-activating interface blockade plus a backup closed-state modulation route. This preserves the profile’s core thesis: prevent entry before replication, mutation expansion, and reservoir seeding.
12. Phase 3 Readiness Statement
The program is now ready for Phase 3 — Synergy Metrics Computation. In that phase, the prioritized candidate classes will be scored using SCF synergy logic against the planned Fibonacci therapeutic stack, with emphasis on:
- orthogonality to RT lethal mutagenesis,
- compatibility with integrase blockade,
- contribution to reservoir-prevention logic,
- resistance-collapse contribution in combination,
- placement strength at Step 1 within the SCF HIV program.
MASTER DOCUMENT REGISTRY INDEX
- SCF-API-HIV-ENTRY-gp120-001
- SCF-FIB-ENTRY-GATE
- SCF-RESERVOIR-PREVENTION
- SCF-P2-HIV-ENTRY-EXTRACTION-001
- SCF-PHASE2-BIOACTIVE-SCF-ANALYSIS-HIV
- SCF-RD-HIV-ENTRY-FIB1
- SCF-MOA-MEA-ENTRY-BLOCKADE-SET
Reply with NEXT for Phase 3 — Synergy Metrics Computation.